1. Protein Tyrosine Kinase/RTK
  2. ALK

NVP-TAE 684 

Cat. No.: HY-10192 Purity: 99.64%
Data Sheet SDS Handling Instructions

NVP-TAE 684 is a highly potent and selective ALK inhibitor, which blocks the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM.

For research use only. We do not sell to patients.
NVP-TAE 684 Chemical Structure

NVP-TAE 684 Chemical Structure

CAS No. : 761439-42-3

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $108 In-stock
5 mg $80 In-stock
10 mg $120 In-stock
50 mg $320 In-stock
100 mg $450 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

    NVP-TAE 684 purchased from MCE. Usage Cited in: ACS Chem Biol. 2012 Dec 21;7(12):1968-74.

    TAE684 inhibits NPM-Ltk. Wild-type embryos are injected with 30 pg of psox10:NPM-Ltk and treated with 3 μM of TAE684. Incident light images at 3 dpf of control uninjected, nontreated embryo (a); NPM-Ltk injected, DMSO-treated sibling (b); and NPM-Ltk injected TAE684-treated siblings (c).

    NVP-TAE 684 purchased from MCE. Usage Cited in: Pigment Cell Melanoma Res. 2016 May;29(3):284-96.

    Ltk inhibitor TAE684 partially rescues the ltkmne phenotype and decreases the number of iridophores. The number of iridophores is reduced in ltkmne/+ larvae treated with ALK inhibitor TAE684 from 82 to 105 hpf.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    NVP-TAE 684 is a highly potent and selective ALK inhibitor, which blocks the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM.

    In Vitro

    TAE684 inhibits the proliferation of Ba/F3 NPM-ALK cells with an ICsub>50 of 3 nM, without affecting the survival of parental Ba/F3 cells at concentrations up to 1 μM. TAE684 inhibits STAT3 and STAT5 phosphorylation in a dose-dependent manner in both Ba/F3 NPM-ALK and Karpas-299 cells. TAE684 induces apoptosis and G1 phase arrest in NPM-ALK-expressing Ba/F3 cells and ALCL patient cell lines[1]. NVP-TAE684 markedly reduces cell survival in both sensitive H3122 and H3122 CR cells, but has little to no effect on the viability of other, non-ALK-dependent cancer cell lines. NVP-TAE684 treatment of H3122 CR cells suppresses phosphorylation of ALK, AKT, and ERK and induces marked apoptosis. TAE684 potently suppresses the survival of Ba/F3 cells expressing the EML4-ALK L1196M mutant[2]. Neurite outgrowth induced by expression of the mALKR1279Q mutant is completely inhibited at 30 nM NVP-TAE684, which is comparable with the response seen with activated wt mALK[3].

    In Vivo

    NVP-TAE684 suppresses lymphomagenesis in two independent models of ALK-positive ALCL and induces regression of established Karpas-299 lymphomas. TAE684 displays appreciable bioavailability and half-life in vivo. TAE684 (1, 3, and 10 mg/kg. p.o.) significantly delays in lymphoma development and shows 100- to 1,000-fold reduction in luminescence signal. The TAE684- (10 mg/kg) treated group appeares healthy and does not display any signs of compound- or disease-related toxicity[1]

    References
    Preparing Stock Solutions
    Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
    1 mM 1.6281 mL 8.1407 mL 16.2813 mL
    5 mM 0.3256 mL 1.6281 mL 3.2563 mL
    10 mM 0.1628 mL 0.8141 mL 1.6281 mL
    Cell Assay
    [1]

    Luciferase-expressing Karpas-299, SU-DHL-1, and Ba/F3 cells and transformed Ba/F3 stably expressing NPM-ALK, BCR-ABL, or TEL-kinase fusion constructs are plated in 384-well plates (25,000 cells per well) and incubated with serial dilutions of TAE684 or DMSO for 2-3 days. Luciferase expression is used as a measure of cell proliferation/survival and is evaluated with the Bright-Glo Luciferase Assay System. ICsub>50 values are generated by using XLFit software. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    NVP-TAE 684 is resuspended in 10% 1-methyl-2-pyrrolidinone/90% PEG 300 solution.

    For in vivo compound efficacy studies, treatment is initiated 72 h after tail vein injection of 1×106 Karpas-299-, Ba/F3 NPM-ALK- or BCR-ABL-expressing cells into female Fox Chase SCIDBeige mice. Mice (n=10 per group) are administered either TAE684 resuspended in 10% 1-methyl-2-pyrrolidinone/90% PEG 300 solution at 1, 3, and 10 mg/kg once daily for 3 weeks or the vehicle solution at the same dosing schedule. Disease progression and compound efficacy is monitored weekly with bioluminescence imaging. To determine the efficacy of TAE684 on established disease, dosing is initiated on day 12, at which time the disease confirmed to be widespread by bioluminescence imaging. For analysis of downstream molecular effects in vivo, mice with established lymphomas are administered vehicle solution or TAE684 (10 mg/kg) for 3 days. At the end of treatment, mice are killed, and lymph nodes are extracted for immunoblotting and histological analysis. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    614.2

    Formula

    C₃₀H₄₀ClN₇O₃S

    CAS No.

    761439-42-3

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    10 mM in DMSO

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    NVP-TAE 684
    Cat. No.:
    HY-10192
    Quantity: